Patents Assigned to Ipsen Pharma S.A.S.
  • Patent number: 9072703
    Abstract: A series of glucose-dependent insulinotropic polypeptide analog compounds, pharmaceutical compositions, and the use of the GIP polypeptide analog compounds as GIP-receptor agonists or antagonists for the treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: July 7, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin Dong
  • Publication number: 20150175665
    Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
    Type: Application
    Filed: March 5, 2015
    Publication date: June 25, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventor: Zheng Xin DONG
  • Patent number: 9056055
    Abstract: The subject of the present invention is a flavored therapeutic composition containing a clay as the active principle, and characterized in that the clay is a dioctahedral smectite and the flavor is encapsulated.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: June 16, 2015
    Assignees: IPSEN PHARMA S.A.S., FIRMENICH S.A.
    Inventors: Jérôme Barra, Denis Le Hazif
  • Publication number: 20150148522
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Application
    Filed: February 5, 2015
    Publication date: May 28, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Zheng Xin DONG, Yeelana SHEN
  • Patent number: 9040482
    Abstract: The present invention relates to novel octapeptide compounds of general formula (I), R-AA1-cyclo(AA2-Tyr3-D-Trp4-AA5-Val6-Cys7)-Thr8-NH2??(I) As these products have a good affinity for certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) of the somatostatin receptors is (are) involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: May 26, 2015
    Assignees: IPSEN PHARMA S.A.S., COMMISSARIAT A L'ENERGIE ATOMIQUE (C.E.A.), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Jean-Christophe Cintrat, Melinda Ligeti, Bernard Rousseau, Franck Artzner, Christophe Tarabout, Marie-Thérèse Paternostre, Nicolas Fay, Roland Cherif-Cheikh, Céline Valery
  • Publication number: 20150111823
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 23, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Zheng Xin Dong, John E Taylor, Rakesh Datta, Michael DeWitt Culler
  • Patent number: 9006274
    Abstract: The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one compound selected from among neuroleptics or products that act on the dopaminergic system for the treatment or prevention of dyskinesias caused by a chemical treatment.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: April 14, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Pierre-Etienne Chabrier De Lassauniere, Michel Auguet, Brigitte Spinnewyn
  • Patent number: 8999940
    Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: April 7, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin Dong
  • Patent number: 8981054
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: March 17, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Rakesh Datta, Zheng Xin Dong
  • Patent number: 8962559
    Abstract: The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogs thereof and the manufacturing process of such pharmaceutical compositions.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: February 24, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Roland Cherif-Cheikh, Fédéric Lacombe, Maria-Luisa Torres Salgado, Perrine Cambriel, Mercé Cardus Malaspina, Isabel Diaz Del Consuelo, Martin Montes, Fabien Jeannerot, Marie Delporte, Anne Brochard, Joël Richard
  • Patent number: 8952128
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: February 10, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
  • Publication number: 20150031615
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2??(I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 29, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventor: Zheng Xin DONG
  • Patent number: 8921322
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Publication number: 20140377354
    Abstract: The subject of the present invention is a flavoured therapeutic composition containing a clay as the active principle, and characterized in that the clay is a dioctahedral smectite and the flavour is encapsulated.
    Type: Application
    Filed: February 12, 2014
    Publication date: December 25, 2014
    Applicants: FIRMENICH S.A., IPSEN PHARMA S.A.S.
    Inventors: Jérôme BARRA, Denis LE HAZIF
  • Patent number: 8877715
    Abstract: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: November 4, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
  • Patent number: 8871706
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogous of native hGhrelin.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: October 28, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Michael DeWitt Culler, Rakesh Datta, John E. Taylor
  • Patent number: 8859729
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2??(I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: October 14, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin Dong
  • Patent number: 8822442
    Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: September 2, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Michael Dewitt Culler, Yeelena Shen
  • Patent number: 8784841
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: July 22, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Patent number: 8759299
    Abstract: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn59)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: June 24, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Nicholas C. Prairie, Maria L. Ufret, Jundong Zhang, Deborah M. Rothman, Jeanne Mary Comstock